DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Neupro (Rotigotine) - Published Studies

 
 



Neupro Related Published Studies

Well-designed clinical trials related to Neupro (Rotigotine)

Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. [2014]

Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. [2014]

Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. [2013]

Drug safety evaluation of rotigotine. [2012]

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. [2010]

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. [2007]

Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. [2007]

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. [2007]

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. [2007]

Well-designed clinical trials possibly related to Neupro (Rotigotine)

Emerging analgesic drugs for Parkinson's disease. [2012]

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. [2010]

Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. [2001]

Other research related to Neupro (Rotigotine)

Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials. [2015]

Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. [2013]

Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease. [2013]

Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. [2013]

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. [2013]

Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. [2013]

Rotigotine for restless legs syndrome. [2009]

High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease. [2009]

Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. [2009]

Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. [2009]

Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. [2008]

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. [2007]

Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. [2006]

Other possibly related research studies

ADMET considerations for restless leg syndrome drug treatments. [2012]

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011]

Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. [2010]

Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study. [2014]

Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. [2013]

The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. [2013]

Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease. [2014]

Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017